Answers are grounded in this paper and cite their sources.
The novel psychoactive substance (NPS) phenomenon represents a major global problem. Despite the methodical inclusion of new analogues in lists of controlled drugs, new compounds continue to circulate, frequently resulting in fatal intoxications. The emergence of N-isopropyl butylone (NiPB) in 2024, found as an adulterant in methamphetamine-based products, underscores the rapidly evolving landscape of NPSs. Despite its structural similarity to potent monoamine transporter inhibitors, specific pharmacological data and information on its effects in consumers are currently lacking. This study aims to characterize the acute physiological, behavioural, and sensorimotor effects of NiPB (0.1–60 mg/kg; i.p.) in male mice, complemented by in silico pharmacokinetic modelling (ADMET Predictor®). NiPB is predicted to undergo N-dealkylation, cleavage of the 3,4-methylendioxy moiety, and N-glucuronidation. Computational profiling predicted high BBB permeability, Vd = 4.37 L/kg, fup > 50%, CYP2D6 and OCT2 inhibition, and hERG blockade (pIC50 = 4.888). In vivo, NiPB induced dose-dependent locomotor stimulation without affecting motor coordination and provoked tachypnoea and visual reflex alterations, while tactile and acoustic responses, as well as thermoregulation, were preserved. In conclusion, this study defines the preliminary toxicological profile of NiPB, indicating that acute exposure may trigger central psychostimulant toxicity in vivo. Furthermore, based on the in silico profiling, targeted experimental studies are required to determine the actual cardiotoxicity and risks of drug–drug interactions associated with NiPB.
No takes yet. Share an insight, caveat, or question.
Bassi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: